Last reviewed · How we verify

NCT03540901

Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude

Completed Phase 4 Last updated 5 November 2021
What this trial tests

Phase 4 trial testing ACETAZOLAMIDE oral capsule in Chronic Obstructive Pulmonary Disease in 112 participants. Completed in 2 August 2018.

Timeline
22 May 2018
Primary endpoint
2 August 2018
2 August 2018

Quick facts

Lead sponsorUniversity of Zurich
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposeprevention
Enrollment112
Start date22 May 2018
Primary completion2 August 2018
Estimated completion2 August 2018
Sites1 location across Kyrgyzstan

Drugs / interventions tested

Conditions studied

Sponsor

University of Zurich

Who can join

Adults 18 to 75, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will evaluate the effect of acetazolamide (375 mg per day) vs. placebo on lung water content by ultrasound at acute altitude exposure in patients with Chronic Obstructive Pulmonary Disease (COPD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ACETAZOLAMIDE oral capsule

Trials testing the same drug.

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other University of Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03540901.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing